<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="55740"><DrugName>quetiapine fumarate (once-daily sustained release tablet), AstraZeneca</DrugName><DrugNamesKey><Name id="43103946">Bipresso</Name><Name id="43103949">Seroquel ER</Name><Name id="43103947">Seroquel SR</Name><Name id="43103948">Seroquel XR</Name><Name id="43103950">Seroquel XRO</Name><Name id="43103953">Xeroquel LP</Name><Name id="42755348">quetiapine</Name><Name id="42755343">quetiapine fumarate</Name></DrugNamesKey><DrugSynonyms><Name><Value>quetiapine fumarate</Value><Types><Type>USAN</Type></Types></Name><Name><Value>quetiapine</Value><Types><Type>INN</Type></Types></Name><Name><Value>quetiapine fumarate (once-daily sustained release tablet), AstraZeneca</Value></Name><Name><Value>FK-949E</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Bipresso</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Seroquel SR</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Seroquel XR</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Seroquel ER</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Seroquel XRO</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Xeroquel LP</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>quetiapine XR</Value></Name><Name><Value>111974-72-2</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>111974-69-7</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="14190">AstraZeneca plc</CompanyOriginator><CompaniesPrimary><Company id="1013295">Astellas Pharma Inc</Company><Company id="14190">AstraZeneca plc</Company><Company id="1015499">Luye Pharma Group Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="1109820">Alvogen Korea</Company><Company id="14346">Bago</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1013295" type="Company"><TargetEntity id="4295876965" type="organizationId">Astellas Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="1015499" type="Company"><TargetEntity id="4295887822" type="organizationId">Luye Pharma Group Ltd</TargetEntity></SourceEntity><SourceEntity id="1109820" type="Company"><TargetEntity id="5037932342" type="organizationId">Alvogen Korea Holdings Ltd</TargetEntity></SourceEntity><SourceEntity id="14190" type="Company"><TargetEntity id="4295894341" type="organizationId">AstraZeneca PLC</TargetEntity></SourceEntity><SourceEntity id="14346" type="Company"><TargetEntity id="5001122404" type="organizationId">Laboratorios Bago SA</TargetEntity></SourceEntity><SourceEntity id="11" type="ciIndication"><TargetEntity id="F10.2" type="ICD10"></TargetEntity><TargetEntity id="10001639" type="MEDDRA"></TargetEntity><TargetEntity id="D000437" type="MeSH"></TargetEntity><TargetEntity id="-1679518733" type="omicsDisease"></TargetEntity><TargetEntity id="1119" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1937" type="ciIndication"><TargetEntity id="F41.1" type="ICD10"></TargetEntity><TargetEntity id="10018075" type="MEDDRA"></TargetEntity><TargetEntity id="32" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1957" type="ciIndication"><TargetEntity id="F30" type="ICD10"></TargetEntity><TargetEntity id="10026749" type="MEDDRA"></TargetEntity><TargetEntity id="52" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="299" type="ciIndication"><TargetEntity id="F20" type="ICD10"></TargetEntity><TargetEntity id="10039626" type="MEDDRA"></TargetEntity><TargetEntity id="D012559" type="MeSH"></TargetEntity><TargetEntity id="-729613619" type="omicsDisease"></TargetEntity><TargetEntity id="65" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3115" type="ciIndication"><TargetEntity id="F31.81" type="ICD10"></TargetEntity><TargetEntity id="296.89" type="ICD9"></TargetEntity><TargetEntity id="10004940" type="MEDDRA"></TargetEntity><TargetEntity id="50" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="4898" type="ciIndication"><TargetEntity id="F33" type="ICD10"></TargetEntity><TargetEntity id="10012378" type="MEDDRA"></TargetEntity><TargetEntity id="-1357758656" type="omicsDisease"></TargetEntity><TargetEntity id="54" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="653" type="ciIndication"><TargetEntity id="F31" type="ICD10"></TargetEntity><TargetEntity id="296" type="ICD9"></TargetEntity><TargetEntity id="10057667" type="MEDDRA"></TargetEntity><TargetEntity id="D001714" type="MeSH"></TargetEntity><TargetEntity id="-1667300745" type="omicsDisease"></TargetEntity><TargetEntity id="47" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="750" type="ciIndication"><TargetEntity id="G47.0" type="ICD10"></TargetEntity><TargetEntity id="10022437" type="MEDDRA"></TargetEntity><TargetEntity id="76" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="93" type="ciIndication"><TargetEntity id="10012378" type="MEDDRA"></TargetEntity><TargetEntity id="D003863" type="MeSH"></TargetEntity><TargetEntity id="-508468160" type="omicsDisease"></TargetEntity><TargetEntity id="53" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="150" type="Action"><TargetEntity id="125" type="Mechanism">Dopamine D2 Antagonists</TargetEntity></SourceEntity><SourceEntity id="13" type="Action"><TargetEntity id="948" type="Mechanism">5-HT2 Antagonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00633" type="ciTarget"><TargetEntity id="80088336218133" type="siTarget">D(2) dopamine receptor</TargetEntity><TargetEntity id="8168" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Schizophrenia - US - Aug-2007</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="1957">Mania</Indication><Indication id="299">Schizophrenia</Indication><Indication id="3115">Bipolar II disorder</Indication><Indication id="4898">Major depressive disorder</Indication><Indication id="653">Bipolar disorder</Indication><Indication id="93">Depression</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="11">Alcoholism</Indication><Indication id="1937">Generalized anxiety disorder</Indication><Indication id="750">Insomnia</Indication></IndicationsSecondary><ActionsPrimary><Action id="13">5-HT 2 receptor antagonist</Action><Action id="150">Dopamine D2 receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2943">Antipsychotic</Action><Action id="2941">Antidepressant</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="660">Oral sustained release formulation</Technology><Technology id="595">Tablet formulation</Technology><Technology id="585">Oral formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>N5A</Code><Name>ANTIPSYCHOTICS</Name></Ephmra><Ephmra><Code>N6A</Code><Name>ANTI-DEPRESSANTS AND MOOD STABILISERS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-02-18T10:26:41.000Z</LastModificationDate><ChangeDateLast>2019-03-16T00:00:00.000Z</ChangeDateLast><AddedDate>2006-07-19T13:40:15.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Developed and launched by &lt;ulink linkID="14190" linkType="Company"&gt;AstraZeneca&lt;/ulink&gt;, and now marketed in most regions worldwide by &lt;ulink linkID="1015499" linkType="Company"&gt;Luye Pharma&lt;/ulink&gt; following an asset purchase, Seroquel SR (Seroquel XR; Seroquel XRO; quetiapine XR; Seroquel ER; Xeroquel LP; Bipresso; FK-949E) is a once-daily, oral sustained-release tablet formulation of the 5-HT 2 and  dopamine  D2 antagonist &lt;ulink linkID="3317" linkType="Drug"&gt;quetiapine fumarate&lt;/ulink&gt;. The product is indicated in the US and EU for the  treatment of schizophrenia,   for the acute treatment or maintenance treatment of manic episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex, for the acute treatment of depressive episodes  associated with bipolar disorder, and as an adjunctive treatment for major depressive  disorder [&lt;ulink linkID="1081894" linkType="Reference"&gt;1081894&lt;/ulink&gt;]. In Japan, the product is indicated for the treatment of depressive symptoms associated with bipolar disorder [&lt;ulink linkID="1957705" linkType="Reference"&gt;1957705&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2007, the product was launched in the US for the acute treatment of schizophrenia [&lt;ulink linkID="831773" linkType="Reference"&gt;831773&lt;/ulink&gt;]; in November 2007, it was approved in the US for the maintenance treatment of schizophrenia [&lt;ulink linkID="851912" linkType="Reference"&gt;851912&lt;/ulink&gt;]. By July 2008, the drug was available in the EU  for schizophrenia [&lt;ulink linkID="930079" linkType="Reference"&gt;930079&lt;/ulink&gt;], [&lt;ulink linkID="930567" linkType="Reference"&gt;930567&lt;/ulink&gt;].  &lt;ulink linkID="1015499" linkType="Company"&gt;Luye Pharma&lt;/ulink&gt; is developing the drug for the Chinese market. In July 2018, the drug  received approval for the treatment of depression arising from bipolar disorder in China [&lt;ulink linkID="2056030" linkType="Reference"&gt;2056030&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In February 2009,  the drug was launched in the US for the acute treatment of bipolar depressive episodes and bipolar I manic and mixed episodes, and the maintenance treatment of bipolar I disorder [&lt;ulink linkID="986015" linkType="Reference"&gt;986015&lt;/ulink&gt;]. In November 2008, it was approved in the EU for bipolar disorder-associated mania and major depressive disorder [&lt;ulink linkID="962768" linkType="Reference"&gt;962768&lt;/ulink&gt;]. In September 2009, the drug was approved in Europe for the prevention of recurrence of bipolar disorder in patients who have responded to quetiapine treatment [&lt;ulink linkID="1045686" linkType="Reference"&gt;1045686&lt;/ulink&gt;]. The drug was launched in Japan  for the treatment of depressive symptoms associated with bipolar disorder in 3Q17 [&lt;ulink linkID="1957705" linkType="Reference"&gt;1957705&lt;/ulink&gt;], [&lt;ulink linkID="2113487" linkType="Reference"&gt;2113487&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2010, the drug had been launched in the US as an adjunctive treatment to antidepressants in adults with major depressive disorder  (MDD) [&lt;ulink linkID="1119693" linkType="Reference"&gt;1119693&lt;/ulink&gt;]. In September 2010, the drug was launched in the UK as an adjunctive therapy in major depressive disorder [&lt;ulink linkID="1355826" linkType="Reference"&gt;1355826&lt;/ulink&gt;]. By October 2010, AstraZeneca had secured approval in  17 EU member states on the drug as an add-on treatment for MDD [&lt;ulink linkID="1142799" linkType="Reference"&gt;1142799&lt;/ulink&gt;]. In November 2011, phase II trials were ongoing  for MDD in Japan [&lt;ulink linkID="1236496" linkType="Reference"&gt;1236496&lt;/ulink&gt;]; however, in February 2014, development was discontinued [&lt;ulink linkID="1521014" linkType="Reference"&gt;1521014&lt;/ulink&gt;]. In December 2009, a Complete Response letter requesting additional information for use of  Seroquel SR as a monotherapy in MDD was issued  by the FDA [&lt;ulink linkID="1062050" linkType="Reference"&gt;1062050&lt;/ulink&gt;]; however no further development has since been reported [&lt;ulink linkID="1176104" linkType="Reference"&gt;1176104&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Seroquel SR was also under development for other indications including the potential treatment of alcoholism   [&lt;ulink linkID="762824" linkType="Reference"&gt;762824&lt;/ulink&gt;], [&lt;ulink linkID="825802" linkType="Reference"&gt;825802&lt;/ulink&gt;]. In December 2007, a phase II trial investigating the efficacy of Seroquel SR in very heavy drinkers with alcohol dependence was initiated. The study was completed in March 2010 [&lt;ulink linkID="1023044" linkType="Reference"&gt;1023044&lt;/ulink&gt;]; however, no further development has since been reported. The product was also under development for the potential treatment of generalized anxiety disorder (GAD) [&lt;ulink linkID="762824" linkType="Reference"&gt;762824&lt;/ulink&gt;], [&lt;ulink linkID="825802" linkType="Reference"&gt;825802&lt;/ulink&gt;]. An sNDA for GAD was filed in May 2008 [&lt;ulink linkID="903791" linkType="Reference"&gt;903791&lt;/ulink&gt;].  In October 2008, AstraZeneca filed for EU approval for short-term and maintenance treatment of GAD [&lt;ulink linkID="954070" linkType="Reference"&gt;954070&lt;/ulink&gt;].  However, by October 2010, the application had been withdrawn and development was presumed to be have been discontinued [&lt;ulink linkID="1142799" linkType="Reference"&gt;1142799&lt;/ulink&gt;]. The product was also under development for the potential treatment of resistant psycho-physiological insomnia. In August 2008, a trial was planned  [&lt;ulink linkID="1515322" linkType="Reference"&gt;1515322&lt;/ulink&gt;]. However, no further development was reported.  &lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;The US patent covering the active ingredient in Seroquel XR (&lt;ulink linkID="IN1476775" linkType="Patent"&gt;US-04879288&lt;/ulink&gt;) expired in March 2012, following pediatric exclusivity. The formulation patent (&lt;ulink linkID="IN2693775" linkType="Patent"&gt;US-05948437&lt;/ulink&gt;) covering Seroquel XR in the US expired in November 2017 following pediatric exclusivity.&lt;/para&gt;&lt;para&gt;In September 2011, AstraZeneca filed Citizen Petitions requesting the FDA  withhold final approval for any generic quetiapine product with labelling that did not contain certain hyperglycemia warning language required for its branded product. In March 2012, the FDA denied the Citizen Petitions. The company filed a lawsuit against the agency to overturn the decision [&lt;ulink linkID="1270415" linkType="Reference"&gt;1270415&lt;/ulink&gt;], [&lt;ulink linkID="1270981" linkType="Reference"&gt;1270981&lt;/ulink&gt;]. Later that month, the District Court denied the company's request and dismissed the case [&lt;ulink linkID="1274350" linkType="Reference"&gt;1274350&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2012, &lt;ulink linkID="21932" linkType="Company"&gt;Lupin&lt;/ulink&gt; filed an ANDA in the US for its generic Seroquel XR product. In November 2012, AstraZeneca commenced patent infringement litigation against Lupin [&lt;ulink linkID="1396542" linkType="Reference"&gt;1396542&lt;/ulink&gt;]. In April 2013, AstraZeneca settled its patent infringement action against Lupin by granting a license to the Seroquel XR product patent, effective November 1, 2016, or earlier, in certain circumstances [&lt;ulink linkID="1459567" linkType="Reference"&gt;1459567&lt;/ulink&gt;]. In May 2017, Lupin received approval for its generic Seroquel XR (50, 150, 200, 300, and 400 mg tablets) in the US [&lt;ulink linkID="2112318" linkType="Reference"&gt;2112318&lt;/ulink&gt;]. In August 2017, Lupin launched the generic [&lt;ulink linkID="2112325" linkType="Reference"&gt;2112325&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2012, &lt;ulink linkID="1027030" linkType="Company"&gt;Amneal Pharmaceuticals&lt;/ulink&gt; filed an ANDA with the FDA for its generic version of Seroquel XR. In August 2012, AstraZeneca commenced patent litigation against Amneal. In January 2013, AstraZeneca settled its litigation with Amneal, by granting a license for the Seroquel XR product patent, which would allow Amneal to market its generic product on November 1, 2016, or earlier under certain circumstances [&lt;ulink linkID="1396542" linkType="Reference"&gt;1396542&lt;/ulink&gt;]. In October 2018, Amneal received approval for its generic version of Seroquel XR (400 mg tablet) [&lt;ulink linkID="2112329" linkType="Reference"&gt;2112329&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2011, a trial took place in the patent infringement litigation regarding the Seroquel XR formulation patent against certain generic drug manufacturers. In March 2012, the Court ruled in favor of AstraZeneca, ruling that &lt;ulink linkID="1022293" linkType="Company"&gt;Anchen Pharmaceuticals&lt;/ulink&gt; (a subsidiary of Par Pharmaceutical), &lt;ulink linkID="1030119" linkType="Company"&gt;Osmotica Pharmaceutical&lt;/ulink&gt;, &lt;ulink linkID="29175" linkType="Company"&gt;Torrent Pharmaceuticals&lt;/ulink&gt; and &lt;ulink linkID="18439" linkType="Company"&gt;Mylan&lt;/ulink&gt; infringed AstraZeneca's patent covering the formulation of Seroquel XR, and upheld the validity of the patent. The decision was subsequently appealed. In February 2013, the Federal Circuit's Appeals Court upheld the prior ruling by the US District Court that the formulation patent of Seroquel XR was valid and infringed. In February 2013, AstraZeneca settled its litigation with Torrent, allowing a license for the Seroquel XR product patent, which would allow Torrent to market its generic product on November 01, 2016, or earlier under certain circumstances [&lt;ulink linkID="1396542" linkType="Reference"&gt;1396542&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2011, &lt;ulink linkID="1016256" linkType="Company"&gt;Intellipharmaceutics&lt;/ulink&gt; filed an ANDA with the FDA for its generic  Seroquel XR product [&lt;ulink linkID="1181381" linkType="Reference"&gt;1181381&lt;/ulink&gt;]; the FDA accepted the filing in May 2011  [&lt;ulink linkID="1188077" linkType="Reference"&gt;1188077&lt;/ulink&gt;]. In July 2012, Intellipharmaceutics and AstraZeneca agreed to settle all outstanding patent litigation regarding the ANDA. Under the agreement, Intellipharmaceutics would be permitted to launch its generic (50, 150, 200, 300 and 400 mg) on November 01, 2016 after FDA approval [&lt;ulink linkID="1312196" linkType="Reference"&gt;1312196&lt;/ulink&gt;]. By October 2016, the ANDA had received  tentative approval; at that time,   Intellipharmaceutics  granted &lt;ulink linkID="1085756" linkType="Company"&gt;Mallinckrodt&lt;/ulink&gt; an exclusive license to market, sell and distribute the generic in the US  [&lt;ulink linkID="1806420" linkType="Reference"&gt;1806420&lt;/ulink&gt;]. In May 2017, final approval was granted following the expiry of the 180-day exclusivity period. At that time, Intellipharmaceutics expected to ship the generic product to Mallinckrodt 'imminently' under its commercialization agreement [&lt;ulink linkID="1926542" linkType="Reference"&gt;1926542&lt;/ulink&gt;]. In June 2017, Mallinckrodt launched Intellipharmaceutics' generic version of Seroquel XR (50, 150, 200, 300 and 400 mg tablets) [&lt;ulink linkID="1935048" linkType="Reference"&gt;1935048&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2008, AstraZeneca filed a patent infringment suit against Handa, following an ANDA filing with a Paragraph IV certification for a generic version of Seroquel XR. In December 2010, &lt;ulink linkID="1048449" linkType="Company"&gt;Handa Pharmaceuticals&lt;/ulink&gt; received tentative FDA approval for a generic version of Seroquel XR tablets (50, 150, 200, 300 and 400 mg). At that time, Handa claimed to be the first company to file an ANDA containing Paragraph IV certification, thereby gaining 180 days of Hatch-Waxman exclusivity [&lt;ulink linkID="1172344" linkType="Reference"&gt;1172344&lt;/ulink&gt;]. In September 2011, AstraZeneca agreed with Handa to resolve their dispute over Handa's proposed generic version of Seroquel XR. Under the agreement, Handa acknowledged the validity and enforceability of the patents-in-suit, and AstraZeneca granted a license to Handa to enter the US market with generic Seroquel XR products on November 01, 2016, or earlier under certain circumstances [&lt;ulink linkID="1270981" linkType="Reference"&gt;1270981&lt;/ulink&gt;], [&lt;ulink linkID="1226958" linkType="Reference"&gt;1226958&lt;/ulink&gt;]. In October 2012, &lt;ulink linkID="28968" linkType="Company"&gt;Par Pharmaceutical&lt;/ulink&gt; acquired Handa's ANDA including the exclusive rights to commercialize the generic product upon final FDA approval [&lt;ulink linkID="1335826" linkType="Reference"&gt;1335826&lt;/ulink&gt;]. In November 2016, Par, an &lt;ulink linkID="1089706" linkType="Company"&gt;Endo International&lt;/ulink&gt; company,  launched its generic version of Seroquel (50, 150, 200 and 300 mg tablets); it was to have 180 days of marketing exclusivity  [&lt;ulink linkID="1868457" linkType="Reference"&gt;1868457&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2008, &lt;ulink linkID="1052220" linkType="Company"&gt;Accord Healthcare&lt;/ulink&gt; filed an ANDA with Paragraph IV certification for a generic version of  Seroquel XR tablets (150, 200, 300 and 400 mg) in the US [&lt;ulink linkID="1896213" linkType="Reference"&gt;1896213&lt;/ulink&gt;]. In September 2008, AstraZeneca filed a US lawsuit against Accord alleging patent infringement of the 437' patent covering Seroquel XR [&lt;ulink linkID="1896246" linkType="Reference"&gt;1896246&lt;/ulink&gt;]. In October 2011, AstraZeneca entered into a settlement agreement with Accord to resolve their dispute over Accord's proposed generic Seroquel XR product. Under the agreement, Accord acknowledged the validity and enforceability of the patents-in-suit, and AstraZeneca granted a license to Accord to enter the US market with generic Seroquel XR products on November 01, 2016, or earlier under certain circumstances [&lt;ulink linkID="1228241" linkType="Reference"&gt;1228241&lt;/ulink&gt;]. In November 2016, the FDA granted approval of Accord's 400 mg generic version and tentative approval of  150, 200 and 300 mg versions   [&lt;ulink linkID="1871782" linkType="Reference"&gt;1871782&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;The formulation patents covering Seroquel XR in the EU expired in 2017 [&lt;ulink linkID="1176104" linkType="Reference"&gt;1176104&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2012, a Dutch District Court upheld the validity of the formulation patent covering Seroquel XR [&lt;ulink linkID="1396542" linkType="Reference"&gt;1396542&lt;/ulink&gt;]. In June 2014, the Dutch Court of Appeal reversed the decision and found the patent invalid [&lt;ulink linkID="1641403" linkType="Reference"&gt;1641403&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2012, a UK High Court ruled that the formulation patent was invalid  [&lt;ulink linkID="1396542" linkType="Reference"&gt;1396542&lt;/ulink&gt;]. In April 2013, the Court of Appeal in the UK denied AstraZeneca’s appeal. In December 2013, the UK Supreme Court decided not to hear an appeal of the decision [&lt;ulink linkID="1540378" linkType="Reference"&gt;1540378&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2012, a Commercial Court in Spain upheld the validity of the formulation patent [&lt;ulink linkID="1396542" linkType="Reference"&gt;1396542&lt;/ulink&gt;]. In October 2013, the Barcelona Court of Appeal reversed the opinion by the Commercial Court in Barcelona and found the Seroquel XR formulation patent invalid. At that time, AstraZeneca intended to appeal the decision [&lt;ulink linkID="1494395" linkType="Reference"&gt;1494395&lt;/ulink&gt;]. In  May 2016, the Spanish Supreme Court affirmed the decision [&lt;ulink linkID="1909620" linkType="Reference"&gt;1909620&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2012, a German Regional Court affirmed that preliminary injunctions had been filed against &lt;ulink linkID="18367" linkType="Company"&gt;Heumann Pharma&lt;/ulink&gt;, &lt;ulink linkID="18186" linkType="Company"&gt;Ratiopharm&lt;/ulink&gt;, &lt;ulink linkID="1061702" linkType="Company"&gt;CT Arzneimittel GmbH&lt;/ulink&gt; and AbZ Pharma GmbH [&lt;ulink linkID="1396542" linkType="Reference"&gt;1396542&lt;/ulink&gt;]. In November 2012, the German Federal Patent Court found the formulation patent to be invalid and all outstanding injunctions were lifted. The patent was also challenged by Accord Healthcare, &lt;ulink linkID="23858" linkType="Company"&gt;Hexal AG&lt;/ulink&gt; and &lt;ulink linkID="20348" linkType="Company"&gt;TEVA Deutschland GmbH&lt;/ulink&gt; [&lt;ulink linkID="1340450" linkType="Reference"&gt;1340450&lt;/ulink&gt;], [&lt;ulink linkID="1396542" linkType="Reference"&gt;1396542&lt;/ulink&gt;]. By March 2014, Ratiopharm, CT Arzneimittel and AbZ were seeking damages relating to the injunction. In January 2015, the Federal Court denied AstraZeneca's appeal [&lt;ulink linkID="1644103" linkType="Reference"&gt;1644103&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2013, generic versions of Seroquel XR had been launched in Austria, Denmark, Germany, Italy, Portugal, the UK and Romania [&lt;ulink linkID="1396542" linkType="Reference"&gt;1396542&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In France, in April 2015, Mylan brought a patent invalidation action against AstraZeneca of the Seroquel XR formulation patent. AstraZeneca brought a claim against Mylan for infringement of the patent. In 3Q15, Mylan launched its generic product at-risk. In November 2015, AstraZeneca obtained a preliminary injunction against Mylan, which was overturned on appeal in December 2015. AstraZeneca had a similar litigation pending against Accord that was settled in January 2016 [&lt;ulink linkID="1745092" linkType="Reference"&gt;1745092&lt;/ulink&gt;]. In July 2016, the Tribunal de Paris found the formulation patent invalid [&lt;ulink linkID="1909620" linkType="Reference"&gt;1909620&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In February 2019, &lt;ulink linkID="1109684" linkType="Company"&gt;Sino Therapeutics&lt;/ulink&gt; filed an ANDA application for its generic version of the drug in China [&lt;ulink linkID="2115841" linkType="Reference"&gt;2115841&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;The formulation patents covering Seroquel XR in Canada expire in 2017 [&lt;ulink linkID="1176104" linkType="Reference"&gt;1176104&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In Canada, AstraZeneca and &lt;ulink linkID="24527" linkType="Company"&gt;Sandoz&lt;/ulink&gt; had been engaged in patent litigation related to Seroquel XR since November 2011 [&lt;ulink linkID="1494395" linkType="Reference"&gt;1494395&lt;/ulink&gt;]. In March 2013, the Federal Court of Canada dismissed AstraZeneca's application to prohibit the Canadian Minister of Health from issuing a Notice of Compliance to &lt;ulink linkID="20348" linkType="Company"&gt;Teva&lt;/ulink&gt; and Sandoz for their generic versions of Seroquel XR [&lt;ulink linkID="1396542" linkType="Reference"&gt;1396542&lt;/ulink&gt;]. Teva then launched its generic Seroquel XR at-risk. In August 2013, AstraZeneca and Sandoz entered into a settlement agreement ending the legal action and allowing Sandoz to launch generic Seroquel XR  [&lt;ulink linkID="1494395" linkType="Reference"&gt;1494395&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;&lt;subtitle&gt;Bipolar disorder&lt;/subtitle&gt;In January 2008, AstraZeneca filed two NDAs in the US for manic and depressive episodes associated with bipolar disorder [&lt;ulink linkID="864165" linkType="Reference"&gt;864165&lt;/ulink&gt;].  In October 2008, the FDA approved the drug for the acute treatment of bipolar depressive episodes and bipolar I manic and mixed episodes, and the maintenance treatment, alongside lithium or &lt;ulink linkID="5265" linkType="Drug"&gt;divalproex&lt;/ulink&gt;, of bipolar I disorder  [&lt;ulink linkID="950620" linkType="Reference"&gt;950620&lt;/ulink&gt;]. In February 2009, the drug was launched in the US for those indications [&lt;ulink linkID="986015" linkType="Reference"&gt;986015&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Depression&lt;/subtitle&gt;An sNDA was filed in May 2008 [&lt;ulink linkID="903791" linkType="Reference"&gt;903791&lt;/ulink&gt;]. In February 2009, AstraZeneca received a complete response from the FDA regarding the sNDA. At that time, the company was evaluating the letter, which requested additional information and proposed labelling revisions [&lt;ulink linkID="987523" linkType="Reference"&gt;987523&lt;/ulink&gt;]. In February 2008, AstraZeneca filed an sNDA for mono-, adjunct and maintenance therapy of MDD [&lt;ulink linkID="881550" linkType="Reference"&gt;881550&lt;/ulink&gt;]. In December 2008, the FDA requested further information regarding the NDA in a complete response letter. AstraZeneca planned to provide a response 'in due course' [&lt;ulink linkID="972906" linkType="Reference"&gt;972906&lt;/ulink&gt;]. In February 2009,  AstraZeneca and the FDA Psychopharmacologic Drugs Advisory Committee (PDAC) convened a meeting to discuss the safety and efficacy of the sNDA for MDD and GAD [&lt;ulink linkID="986798" linkType="Reference"&gt;986798&lt;/ulink&gt;]. In April 2009, the FDA's committee concluded that Seroquel SR was effective as a monotherapy and adjunctive therapy for MDD and as monotherapy for GAD and safe as an adjunctive treatment for MDD, but unsafe as monotherapy for MDD or GAD. The company planned further discussions with the FDA [&lt;ulink linkID="999103" linkType="Reference"&gt;999103&lt;/ulink&gt;]. The drug was approved by the FDA as an adjunctive treatment to antidepressants in adults  with MDD in December 2009. At that time, the agency issued a Complete Response letter requesting additional information for the sNDA for use of  Seroquel SR as a monotherapy in MDD [&lt;ulink linkID="1062050" linkType="Reference"&gt;1062050&lt;/ulink&gt;]; however, no development has since been reported for this indication [&lt;ulink linkID="1176104" linkType="Reference"&gt;1176104&lt;/ulink&gt;]. By July 2010, AstraZeneca had withdrawn the filing for GAD in the US [&lt;ulink linkID="1119693" linkType="Reference"&gt;1119693&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Schizophrenia&lt;/subtitle&gt;In July 2006, AstraZeneca submitted an NDA for schizophrenia [&lt;ulink linkID="678844" linkType="Reference"&gt;678844&lt;/ulink&gt;]. In May 2007, the FDA approved the product at doses of 400, 600, and 800 mg/day for the treatment of schizophrenia [&lt;ulink linkID="796076" linkType="Reference"&gt;796076&lt;/ulink&gt;], and it was launched in August 2007 [&lt;ulink linkID="831773" linkType="Reference"&gt;831773&lt;/ulink&gt;].  In November 2007, the product was additionally approved in the US for the maintenance treatment of schizophrenia [&lt;ulink linkID="851912" linkType="Reference"&gt;851912&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;&lt;subtitle&gt;Anxiety&lt;/subtitle&gt;In October 2008, AstraZeneca filed for EU approval for short-term and maintenance treatment of GAD [&lt;ulink linkID="954070" linkType="Reference"&gt;954070&lt;/ulink&gt;]. By October 2010, AstraZeneca had withdrawn the application for generalized anxiety disorder [&lt;ulink linkID="1142799" linkType="Reference"&gt;1142799&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Depression&lt;/subtitle&gt;In June 2008, AstraZeneca filed for EU approval of the drug for MDD, under the MRP [&lt;ulink linkID="915411" linkType="Reference"&gt;915411&lt;/ulink&gt;]. In May 2009, the company referred the application to the CHMP, after the Netherlands Health Authority, acting as the reference state, refused the application [&lt;ulink linkID="1013913" linkType="Reference"&gt;1013913&lt;/ulink&gt;]. In April 2010, the CHMP of the EMA recommended approval of the drug as adjunctive treatment for major depressive episodes in patients with MDD, who have had sub-optimal response to other antidepressants [&lt;ulink linkID="1093317" linkType="Reference"&gt;1093317&lt;/ulink&gt;]. In September 2010, the EC issued a positive decision on approval of the drug, and at that time the drug was launched in the UK [&lt;ulink linkID="1355826" linkType="Reference"&gt;1355826&lt;/ulink&gt;]. AstraZeneca would continue with the application to gain local approval in the 17 member states under the mutual recognition procedure [&lt;ulink linkID="1128002" linkType="Reference"&gt;1128002&lt;/ulink&gt;]. By October 2010, AstraZeneca had secured approval in  17 EU member states [&lt;ulink linkID="1142799" linkType="Reference"&gt;1142799&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Bipolar disorder&lt;/subtitle&gt;In February 2008, AstraZeneca filed for EU approval of extended-release quetiapine fumarate for bipolar disorder-associated mania and depression, under the MRP [&lt;ulink linkID="875833" linkType="Reference"&gt;875833&lt;/ulink&gt;]. In November 2008, the drug was approved for the treatment of major depressive episodes in bipolar disorder, as well as moderate-to-severe manic episodes in bipolar disorder [&lt;ulink linkID="962768" linkType="Reference"&gt;962768&lt;/ulink&gt;].  In September 2009, the drug was approved in Europe for the prevention of recurrence of bipolar disorder in patients who have responded to quetiapine treatment [&lt;ulink linkID="1045686" linkType="Reference"&gt;1045686&lt;/ulink&gt;].   &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Schizophrenia&lt;/subtitle&gt;In October 2006, an MAA for schizophrenia was filed [&lt;ulink linkID="733288" linkType="Reference"&gt;733288&lt;/ulink&gt;]. In August 2007, the drug was approved in the Netherlands [&lt;ulink linkID="825802" linkType="Reference"&gt;825802&lt;/ulink&gt;]; the company was to seek approvals across Europe utilizing the Mutual Recognition Procedure (MRP) [&lt;ulink linkID="846782" linkType="Reference"&gt;846782&lt;/ulink&gt;]. In December 2007, the MRP was completed and the company was seeking national licenses [&lt;ulink linkID="872437" linkType="Reference"&gt;872437&lt;/ulink&gt;]. By July 2008, the drug was available in the EU  for schizophrenia [&lt;ulink linkID="930079" linkType="Reference"&gt;930079&lt;/ulink&gt;], [&lt;ulink linkID="930567" linkType="Reference"&gt;930567&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In August 2016, the company submitted an NDA to the Japanese MHLW  for the improvement of depressive symptoms associated with bipolar disorder based upon the request from the evaluation committee on an approved or off-label drugs with high medical needs [&lt;ulink linkID="1786675" linkType="Reference"&gt;1786675&lt;/ulink&gt;], [&lt;ulink linkID="1869274" linkType="Reference"&gt;1869274&lt;/ulink&gt;]; in June 2017, the first committee on New Drugs, Pharmaceutical Affairs and Food Sanitation Council recommended approval for depression in bipolar disorder [&lt;ulink linkID="1938339" linkType="Reference"&gt;1938339&lt;/ulink&gt;]. In July 2017, approval was granted in Japan  for the treatment of depressive symptoms associated with bipolar disorder. In August 2017, the product was added to the NHI listing in Japan. The product would be distributed in Japan by &lt;ulink linkID="1127603" linkType="Company"&gt;Kyowa Pharmaceutical&lt;/ulink&gt;  (a subsidiary of &lt;ulink linkID="21932" linkType="Company"&gt;Lupin&lt;/ulink&gt;) [&lt;ulink linkID="1957705" linkType="Reference"&gt;1957705&lt;/ulink&gt;].  The drug was launched in Japan in 3Q17 [&lt;ulink linkID="2113487" linkType="Reference"&gt;2113487&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In March 2016, a filing for approval was submitted in China; in June 2018, review of the application was concluded though the outcome was not published yet [&lt;ulink linkID="2046515" linkType="Reference"&gt;2046515&lt;/ulink&gt;]. In July 2018, the drug  received approval for  depression arising from bipolar disorder in China [&lt;ulink linkID="2056030" linkType="Reference"&gt;2056030&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2010, a filing for approval was filed in China [&lt;ulink linkID="1954545" linkType="Reference"&gt;1954545&lt;/ulink&gt;]; in October 2013, the drug was approved in China for schizophrenia [&lt;ulink linkID="1501534" linkType="Reference"&gt;1501534&lt;/ulink&gt;]. The drug was assumed to be launched in China as Seroquel XR shortly after its approval there in 2013 [&lt;ulink linkID="1954544" linkType="Reference"&gt;1954544&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;In October 2006, AstraZeneca made a submission to the Canadian regulatory authorities for schizophrenia [&lt;ulink linkID="733288" linkType="Reference"&gt;733288&lt;/ulink&gt;]. In September 2007, approval was granted in Canada for schizophrenia [&lt;ulink linkID="846782" linkType="Reference"&gt;846782&lt;/ulink&gt;], and by July 2008, the drug was available [&lt;ulink linkID="930567" linkType="Reference"&gt;930567&lt;/ulink&gt;]. In May 2009, Health Canada approved the drug for MDD [&lt;ulink linkID="1013913" linkType="Reference"&gt;1013913&lt;/ulink&gt;]; launch was presumed to have occurred for that indicaton shortly after.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;By January 2008, the formulation was approved in Korea for schizophrenia  [&lt;ulink linkID="947111" linkType="Reference"&gt;947111&lt;/ulink&gt;]. By March 2010, the agent had been made available for schizophrenia, bipolar disorder and depression [&lt;ulink linkID="1527715" linkType="Reference"&gt;1527715&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 2008, Seroquel XR was assumed to have been launched shortly after approval in Taiwan for the treatment of schizophrenia, manic episodes associated with bipolar disorder, depressive episodes associated with bipolar disorder, and mixed episodes [&lt;ulink linkID="1515617" linkType="Reference"&gt;1515617&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;By June 2013, the drug had  been approved and was presumed to be launched in Argentina for schizophrenia [&lt;ulink linkID="2115657" linkType="Reference"&gt;2115657&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2012, the drug had been approved in Brazil as Seroquel XRO [&lt;ulink linkID="1647989" linkType="Reference"&gt;1647989&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;In July 2006, a US placebo-controlled phase IV study (IRUSQUET408, &lt;ulink linkID="21186" linkType="Protocol"&gt;NCT00352469&lt;/ulink&gt;) was planned. This was to determine whether Seroquel SR could reduce alcohol use, prolong sobriety, reduce craving and reduce anxiety in 20 alcohol-dependent patients with comorbid anxiety. This trial was expected to start in August 2006 [&lt;ulink linkID="678946" linkType="Reference"&gt;678946&lt;/ulink&gt;].&lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Schizophrenia&lt;/subtitle&gt;In March 2007, data from two phase III studies were presented at the European Congress of Psychiatry in Madrid, Spain. The first randomized, double-blind study compared 400, 600 and 800 mg daily doses of the drug with placebo in 588 patients with acute schizophrenia. There was a significant improvement in positive and negative syndrome scale (PANSS) scores in all dose groups. After 6 weeks of treatment, reductions of 24.8, 30.9 and 31.3 were seen in the 400, 600, and 800 mg dose groups, respectively, compared with an 18.8 point reduction for placebo. Subjects also had significantly better scores on the clinical global impression severity scale compared with placebo. A second randomized, double-blind study examined time-to-first psychiatric relapse in 197 patients with clinically stable schizophrenia. Subjects were treated with a mean 669 mg daily dose of Seroquel SR or placebo. Seroquel treated patients experienced a significant 87% risk reduction of relapse compared with those on placebo. This effect was large enough to stop the trial early. In both studies, the most common adverse events were generally mild or moderate, and did not lead to withdrawal [&lt;ulink linkID="775721" linkType="Reference"&gt;775721&lt;/ulink&gt;]. Similar data were presented in May 2007 at the annual meeting of the American Psychiatric Association in San Diego, CA [&lt;ulink linkID="797884" linkType="Reference"&gt;797884&lt;/ulink&gt;] .&lt;/para&gt;&lt;para&gt;In November 2004,  a phase III study (&lt;ulink linkID="36215" linkType="Protocol"&gt;NCT00206128&lt;/ulink&gt;, D1444C00146) was initiated. It was to enroll 550 schizophrenia patients  who had been treated with twice-daily quetiapine and switch them to Seroquel SR to assess non-inferiority. The primary outcome included number of subjects who discontinued treatment because of lack of efficacy or whose PANSS score increased by 20% or more. The secondary outcome was change in PANSS total score between day 0 and day 42 [&lt;ulink linkID="678957" linkType="Reference"&gt;678957&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Major depressive disorder&lt;/subtitle&gt;In  May 2015, results from a post hoc analysis of pooled data from two randomized, placebo-controlled studies data were presented at the 168th APA Annual Meeting in Toronto, Canada. Primary analysis of pooled data demonstrated that quetiapine XR produced significant improvements in baseline Montgomery-Asberg Depression Rating Scale at week 6 when compared to placebo. Safety and tolerability of quetiapine XR were comparable between antidepressant groups and consistent with the published safety profile of quetiapine XR [&lt;ulink linkID="1663446" linkType="Reference"&gt;1663446&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2007, clinical data were presented at the 7th International Forum on Mood and Anxiety Disorders in Budapest, Hungary. Two phase III, randomised, double-blind depression trials assessed the drug as a monotherapy, and as an adjunctive treatment for antidepressant-refractory depression. Total symptom score in the monotherapy study was reduced after 6 weeks of treatment with 150 or 300 mg of Seroquel SR by 14.81 and 15.29 points, respectively, compared with 11.18 points for placebo. In the adjunctive therapy trial, 150 or 300 mg of the drug reduced the symptom score by 15.26 and 14.94 points, respectively, compared with 12.21 for antidepressants alone. The drug was generally well tolerated with dry mouth, sedation or fatigue, somnolence and dizziness observed. Elevated blood glucose levels were also seen [&lt;ulink linkID="858113" linkType="Reference"&gt;858113&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2006, a phase III study (AMBER, &lt;ulink linkID="34887" linkType="Protocol"&gt;NCT00351169&lt;/ulink&gt;, D1448C00004) was initiated. It was to recruit 450 patients with major depressive disorder  and administer them placebo, escitalopram or Seroquel SR for 8 weeks and then assess efficacy using the MADRS score [&lt;ulink linkID="678952" linkType="Reference"&gt;678952&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2006, a parallel-group, placebo-controlled, phase III study of Seroquel SR (PEARL, &lt;ulink linkID="34750" linkType="Protocol"&gt;NCT00326105&lt;/ulink&gt;, D1448C00006) was initiated in up to 450 patients with major depressive disorder, who were unresponsive to existing therapies. This study  was to compare an antidepressant with or without Seroquel SR  [&lt;ulink linkID="669180" linkType="Reference"&gt;669180&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2006, a placebo-controlled, phase III study of Seroquel SR (OPAL, &lt;ulink linkID="34751" linkType="Protocol"&gt;NCT00326144&lt;/ulink&gt;, D1448C00003) was initiated in up to 300 US patients with major depressive order. Efficacy was to be assessed by improvement in MADRS score at week 8 [&lt;ulink linkID="669179" linkType="Reference"&gt;669179&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2005, a placebo-controlled, phase III study (AMETHYST, &lt;ulink linkID="35093" linkType="Protocol"&gt;NCT00278941&lt;/ulink&gt;, D1448C00005) of Seroquel SR was initiated in patients with major depressive disorder.  The study was expected to enroll 2310 patients  [&lt;ulink linkID="669186" linkType="Reference"&gt;669186&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2005, a placebo-controlled, phase III study (ONYX, &lt;ulink linkID="34888" linkType="Protocol"&gt;NCT00351910&lt;/ulink&gt;, D1448C00007) was initiated. It was to recruit 450 patients with major depressive disorder and administer them Seroquel SR in combination with an antidepressant or antidepressant alone. Antidepressants included amitriptyline, bupropion, citalopram, duloxetine, escitalopram, fluoxetine, paroxetine and sertraline. Efficacy and quality of life were to be assessed [&lt;ulink linkID="678954" linkType="Reference"&gt;678954&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2011, phase II trials were ongoing  for MDD in Japan [&lt;ulink linkID="1236496" linkType="Reference"&gt;1236496&lt;/ulink&gt;]; however, in February 2014, development was discontinued [&lt;ulink linkID="1521014" linkType="Reference"&gt;1521014&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Japanese phase I trials in depression were ongoing in August 2009 [&lt;ulink linkID="1033843" linkType="Reference"&gt;1033843&lt;/ulink&gt;]. In February 2010, 	an open-label, non-randomized, single-group assignment, phase I trial (&lt;ulink linkID="146811" linkType="Protocol"&gt;NCT01903200&lt;/ulink&gt;; 6949-CL-0002) was initiated in patients (n = 16) with MDD in Japan to evaluate the safety and tolerability of multiple dose of FK-949E. In September 2011, the trial was completed [&lt;ulink linkID="1457567" linkType="Reference"&gt;1457567&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Generalized anxiety disorder&lt;/subtitle&gt;In April 2008, data supporting filing for GAD were to be presented at the 161st annual meeting of the American Psychiatric Association in Washington DC in  May 2008 [&lt;ulink linkID="899448" linkType="Reference"&gt;899448&lt;/ulink&gt;]. In September 2008, similar data were presented at the 21st European College of Neuropsychopharmacology Congress in Barcelona, Spain [&lt;ulink linkID="954070" linkType="Reference"&gt;954070&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2007, clinical data were presented at the 7th International Forum on Mood and Anxiety Disorders in Budapest, Hungary. An anxiety study evaluated the drug as a monotherapy. Anxiety symptom scores were reduced by 13.95 and 15.96 points for 50 and 150 mg of Seroquel XR, respectively, compared with 12.30 points for placebo. The drug was generally well tolerated with dry mouth, sedation or fatigue, somnolence and dizziness observed. Elevated blood glucose levels were also seen [&lt;ulink linkID="858113" linkType="Reference"&gt;858113&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2006, a placebo- and active-controlled, phase III study (SILVER, &lt;ulink linkID="31180" linkType="Protocol"&gt;NCT00322595&lt;/ulink&gt;, D1448C00011) was initiated. It was to enroll 800 GAD patients and administer them placebo, paroxetine or Seroquel SR. Anxiety scores and response rates were to be assessed at day 57. The study was initiated in May 2006 [&lt;ulink linkID="678950" linkType="Reference"&gt;678950&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2006, a phase III study (&lt;ulink linkID="32607" linkType="Protocol"&gt;NCT00314210&lt;/ulink&gt;, D1448C00012) was initiated. It was to enroll 176 GAD patients and administer them Seroquel SR or placebo. The primary endpoint was time to anxiety event and the secondary endpoints  were number of anxiety events and change in HAM-A, MADRS and PRO scores [&lt;ulink linkID="678958" linkType="Reference"&gt;678958&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;&lt;subtitle&gt;Bipolar disorder&lt;/subtitle&gt;In January 2011, a multi center, double blind, parallel assigned, randomized, placebo controlled  phase III trial (&lt;ulink linkID="72941" linkType="Protocol"&gt;NCT01256177&lt;/ulink&gt;;D144CC00005)  was initiated to evaluate the efficacy and safety of quetiapine fumarate  extended release as monotherapy in the treatment of patients    (n=361) with bipolar depression in China. In December 2012, tha trial was completed [&lt;ulink linkID="1737773" linkType="Reference"&gt;1737773&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2011, Astellas was preparing for phase III trials of the formulation in Japan for bipolar disorder-associated depressive episodes, following request from the MHLW as a result of a review by the "Review Committee on Unapproved Drugs and Indications with High Medical Needs" [&lt;ulink linkID="1237360" linkType="Reference"&gt;1237360&lt;/ulink&gt;]. In August 2012, it was listed as being in phase III trials on Astellas's pipeline for the indication [&lt;ulink linkID="1324547" linkType="Reference"&gt;1324547&lt;/ulink&gt;]; in February 2015, this was still the case [&lt;ulink linkID="1630716" linkType="Reference"&gt;1630716&lt;/ulink&gt;]. In February 2015, an open-label, two-way crossover, randomized, phase III trial (&lt;ulink linkID="222556" linkType="Protocol"&gt;NCT02362412&lt;/ulink&gt;; 6949-CL-0023) was initiated in Japan, in patients (expected n = 20) with bipolar disorder, to assess the efficacy, safety, and pharmacokinetics of  FK-949E. At that time, the trial was expected to complete in October 2016 [&lt;ulink linkID="1636496" linkType="Reference"&gt;1636496&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2008, a bipolar mania study had been completed. It compared Seroquel XR with placebo in 316 patients, with a primary endpoint of change from baseline in Young Mania Rating Scale total score at week 3. The mean change with 400 to 800 mg/day of Seroquel XR was -14.34 compared with -10.52 for placebo. The most common drug side effects were somnolence, dry mouth, dizziness, constipation, weight gain, dysarthria and nasal congestion [&lt;ulink linkID="950620" linkType="Reference"&gt;950620&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2008, a bipolar depression study had been completed. It compared Seroquel XR with placebo in 280 patients, with a primary endpoint of change in Montgomery-Asberg Depression Rating Scale total score at week 8. The mean change with 300 mg/day of Seroquel XR was -17.4 compared with -11.9 for placebo. The most common drug side effects were somnolence, dry mouth, increased appetite, weight gain, dyspepsia and fatigue [&lt;ulink linkID="950620" linkType="Reference"&gt;950620&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2007, a  placebo-controlled, randomized, double-blind, phase III trial (&lt;ulink linkID="31469" linkType="Protocol"&gt;NCT00422123&lt;/ulink&gt;, D144CC00004) was initiated in subjects (expected n = 447) with acute bipolar mania in the US. The subjects were to receive the drug over 3 weeks. The primary endpoint was change from baseline in the YMRS score at final visit and secondary endpoints included changes from baseline at other timepoints [&lt;ulink linkID="762879" linkType="Reference"&gt;762879&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2006, a  placebo-controlled, randomized, double-blind, phase III trial (&lt;ulink linkID="31468" linkType="Protocol"&gt;NCT00422214&lt;/ulink&gt;, D144CC00002) was initiated in subjects (expected n = 400) with acute bipolar depression in the US. The subjects were to receive the drug over 3 weeks. The primary endpoint was change from baseline in the MADRS score at final visit and secondary endpoints included changes from baseline at other timepoints [&lt;ulink linkID="762842" linkType="Reference"&gt;762842&lt;/ulink&gt;]. In   May 2014, further data were presented at the 167th Annual Meeting of the APA in New York, NY. Significantly greater reduction in mean MADRS score was observed in the quetiapine-XR group at week 1, which was maintained to week 8 when compared with placebo group [&lt;ulink linkID="1553962" linkType="Reference"&gt;1553962&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Alcoholism&lt;/subtitle&gt;In December 2007, a randomized, double-blind, parallel, placebo-controlled phase II trial (&lt;ulink linkID="33861" linkType="Protocol"&gt;NCT00498628&lt;/ulink&gt;) was initiated in very heavy drinkers (expected n = 230) with alcohol dependence in the US. Patients were randomized to receive placebo or sustained-release quetiapine, daily for 12 weeks. The primary endpoint was the percentage of days of heavy drinking during weeks 3 and 11 of the study period. The study was completed in March 2010  [&lt;ulink linkID="1023044" linkType="Reference"&gt;1023044&lt;/ulink&gt;]; however, no development has since been reported for this indication.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other studies&lt;/subtitle&gt;In May 2014, data from a randomized, double-blind, controlled study performed in 95 borderline personality disorder patients were presented at the 167th Annual Meeting of the APA in New York, NY. Treatment with extended-release quetiapine reduced Zanarini rating scale total scores from baseline. The respective visit 10 response rates were 62, 82 and 67% in the placebo, 150 and 300 mg extended-release quetiapine groups [&lt;ulink linkID="1553532" linkType="Reference"&gt;1553532&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2013, data from randomized, placebo-controlled clinical trials  in patients with acute bipolar disorder and comorbid generalized anxiety disorder were presented at the 166th APA meeting in San Francisco, CA. Patients (n = 100) received quetiapine-XR (150 to 300 mg/day) or placebo as monotherapy or adjunctive therapy for 8 weeks. Among patients treated with quetiapine-XR and placebo, the changes in Hamilton depression rating scale-17 items (HAMD-17) total scores were not statistically significant, and also no differences were observed in Kaplan-Meier analysis of time to HAMD-17 response [&lt;ulink linkID="1459644" linkType="Reference"&gt;1459644&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2008, a randomized, double-blind, placebo-controlled, crossover trial (D1443L00065) was planned to be initiated in Taiwan to assess the efficacy and safety of low dose quetiapine sustained release formulation in the treatment of patients (estimated Taiwan n = 30, global N/A) with resistant psycho-physiological insomnia. By November 2008, the recruitment had not been started yet [&lt;ulink linkID="1515322" linkType="Reference"&gt;1515322&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="4898">Major depressive disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-09-02T00:00:00.000Z</StatusDate><Source id="1128002" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="X0">Africa</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-10-01T00:00:00.000Z</StatusDate><Source id="2113487" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="X0">Africa</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3115">Bipolar II disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-07-22T00:00:00.000Z</StatusDate><Source id="2056030" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-07-29T00:00:00.000Z</StatusDate><Source id="1119693" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="4898">Major depressive disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-05-29T00:00:00.000Z</StatusDate><Source id="1013913" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-11-12T00:00:00.000Z</StatusDate><Source id="962768" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="X0">Africa</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="4898">Major depressive disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-02-23T00:00:00.000Z</StatusDate><Source id="986015" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="4898">Major depressive disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="X2">Asia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-07-31T00:00:00.000Z</StatusDate><Source id="930079" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="XL">Eastern Europe</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="4898">Major depressive disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="XL">Eastern Europe</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="4898">Major depressive disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-07-31T00:00:00.000Z</StatusDate><Source id="930079" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="X2">Asia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="4898">Major depressive disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1957">Mania</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-11-12T00:00:00.000Z</StatusDate><Source id="962768" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-08-31T00:00:00.000Z</StatusDate><Source id="831773" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="XL">Eastern Europe</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="4898">Major depressive disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="X2">Asia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-08-01T00:00:00.000Z</StatusDate><Source id="930567" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1937">Generalized anxiety disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-10-28T00:00:00.000Z</StatusDate><Source id="1142799" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1109820">Alvogen Korea</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1937">Generalized anxiety disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-07-29T00:00:00.000Z</StatusDate><Source id="1119693" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1109820">Alvogen Korea</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1109820">Alvogen Korea</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="4898">Major depressive disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-02-03T00:00:00.000Z</StatusDate><Source id="1521014" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14346">Bago</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="750">Insomnia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-02-28T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="11">Alcoholism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-02-17T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-10-08T00:00:00.000Z</StatusDate><Source id="1897347" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-12-20T00:00:00.000Z</StatusDate><Source id="1178049" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-10-08T00:00:00.000Z</StatusDate><Source id="1897347" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="X0">Africa</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="XE">South America</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="X2">Asia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="X0">Africa</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="4898">Major depressive disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="X2">Asia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="4898">Major depressive disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="X2">Asia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="XL">Eastern Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="4898">Major depressive disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="4898">Major depressive disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="XE">South America</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="XE">South America</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="4898">Major depressive disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-10-08T00:00:00.000Z</StatusDate><Source id="1897347" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="XL">Eastern Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-19T00:00:00.000Z</StatusDate><Source id="2115657" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="XL">Eastern Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="X0">Africa</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="4898">Major depressive disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="11">Alcoholism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-12-31T00:00:00.000Z</StatusDate><Source id="1023044" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-12-20T00:00:00.000Z</StatusDate><Source id="1178049" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-11-23T00:00:00.000Z</StatusDate><Source id="1351440" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-10-14T00:00:00.000Z</StatusDate><Source id="1447543" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-02-15T00:00:00.000Z</StatusDate><Source id="1456378" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-07-13T00:00:00.000Z</StatusDate><Source id="1515615" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-07-13T00:00:00.000Z</StatusDate><Source id="1515615" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="4898">Major depressive disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-11-01T00:00:00.000Z</StatusDate><Source id="1236496" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-01-31T00:00:00.000Z</StatusDate><Source id="947111" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="750">Insomnia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-08-31T00:00:00.000Z</StatusDate><Source id="1515322" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-11-12T00:00:00.000Z</StatusDate><Source id="962768" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1957">Mania</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-11-12T00:00:00.000Z</StatusDate><Source id="962768" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="4898">Major depressive disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-09-02T00:00:00.000Z</StatusDate><Source id="1128002" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-08-01T00:00:00.000Z</StatusDate><Source id="1324547" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-01T00:00:00.000Z</StatusDate><Source id="1527715" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-01T00:00:00.000Z</StatusDate><Source id="1527715" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-01T00:00:00.000Z</StatusDate><Source id="1527715" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-10-24T00:00:00.000Z</StatusDate><Source id="1501534" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-12-03T00:00:00.000Z</StatusDate><Source id="1954545" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-08-09T00:00:00.000Z</StatusDate><Source id="1786675" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-01-11T00:00:00.000Z</StatusDate><Source id="1737773" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-12-31T00:00:00.000Z</StatusDate><Source id="1954544" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1109820">Alvogen Korea</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-10-08T00:00:00.000Z</StatusDate><Source id="1897347" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1109820">Alvogen Korea</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-10-08T00:00:00.000Z</StatusDate><Source id="1897347" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1109820">Alvogen Korea</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-10-08T00:00:00.000Z</StatusDate><Source id="1897347" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-03-14T00:00:00.000Z</StatusDate><Source id="2046515" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-11-12T00:00:00.000Z</StatusDate><Source id="1647989" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="4898">Major depressive disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-11-12T00:00:00.000Z</StatusDate><Source id="1647989" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-11-12T00:00:00.000Z</StatusDate><Source id="1647989" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate><Source id="2049955" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1015499">Luye Pharma Group Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3115">Bipolar II disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-07-22T00:00:00.000Z</StatusDate><Source id="2056030" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-05-29T00:00:00.000Z</StatusDate><Source id="1013913" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-07-03T00:00:00.000Z</StatusDate><Source id="1957705" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1515617" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1515617" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14346">Bago</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-19T00:00:00.000Z</StatusDate><Source id="2115657" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14346">Bago</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-12-31T00:00:00.000Z</StatusDate><Source id="2117369" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14346">Bago</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-19T00:00:00.000Z</StatusDate><Source id="2115657" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-07-18T00:00:00.000Z</StatusDate><Source id="678844" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-05-18T00:00:00.000Z</StatusDate><Source id="796076" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-10-19T00:00:00.000Z</StatusDate><Source id="733288" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-10-19T00:00:00.000Z</StatusDate><Source id="733288" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="WO">World</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-09-30T00:00:00.000Z</StatusDate><Source id="678954" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="WO">World</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-11-30T00:00:00.000Z</StatusDate><Source id="678957" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="WO">World</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-02-01T00:00:00.000Z</StatusDate><Source id="762824" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1937">Generalized anxiety disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-03-31T00:00:00.000Z</StatusDate><Source id="678958" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-12-31T00:00:00.000Z</StatusDate><Source id="872437" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-09-27T00:00:00.000Z</StatusDate><Source id="846782" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-08-29T00:00:00.000Z</StatusDate><Source id="825802" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-01-02T00:00:00.000Z</StatusDate><Source id="864165" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1937">Generalized anxiety disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-03-31T00:00:00.000Z</StatusDate><Source id="678958" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-02-11T00:00:00.000Z</StatusDate><Source id="875833" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="653">Bipolar disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-10-10T00:00:00.000Z</StatusDate><Source id="950620" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-02-29T00:00:00.000Z</StatusDate><Source id="881550" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1937">Generalized anxiety disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-05-08T00:00:00.000Z</StatusDate><Source id="903791" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-12-04T00:00:00.000Z</StatusDate><Source id="1062050" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-06-11T00:00:00.000Z</StatusDate><Source id="915411" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1937">Generalized anxiety disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-10-20T00:00:00.000Z</StatusDate><Source id="954070" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00018"><Name>5-HT 2 receptor</Name><SwissprotNumbers></SwissprotNumbers></Target><Target id="PTGT-00633"><Name>Dopamine D2 receptor</Name><SwissprotNumbers><Swissprot>O73810</Swissprot><Swissprot>P14416</Swissprot><Swissprot>P20288</Swissprot><Swissprot>P52702</Swissprot><Swissprot>P60026</Swissprot><Swissprot>P61168</Swissprot><Swissprot>P61169</Swissprot><Swissprot>Q9GJU1</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2117369" linkType="reference" linkID="2117369"&gt;2117369&lt;/ulink&gt;]
							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Deal Summary Added/Updated</Reason><Description>Deal summary added/updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1013295">Astellas Pharma Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="1015499">Luye Pharma Group Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1051273">Alvogen Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="14190">AstraZeneca plc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>4</CountTotal></Company><Company><Company id="14346">Bago</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="21932">Lupin Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>3</CountActive><CountInactive>0</CountInactive><CountTotal>3</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>c1ccc2c(c1)C(=Nc3ccccc3S2)N4CCN(CC4)CCOCCO</Smiles><Smiles>c1ccc2c(c1)C(=Nc3ccccc3S2)N4CCN(CC4)CCOCCO.c1ccc2c(c1)C(=Nc3ccccc3S2)N4CCN(CC4)CCOCCO.C(=C/C(=O)O)\C(=O)O</Smiles></StructureSmiles><Deals><Deal id="122176" title="Fujisawa to market AstraZeneca's Seroquel in Japan    "></Deal><Deal id="136489" title="AstraZeneca to grant Handa Pharmaceuticals marketing rights to generic Seroquel XR in litigation settlement"></Deal><Deal id="236618" title="Alvogen to commercialize Astrazeneca's Seroquel for certain neurological disorders"></Deal><Deal id="236998" title="KYOWA Pharmaceutical to distribute Astellas Pharma's quetiapine fumarate in Japan   "></Deal><Deal id="240791" title="Par to market authorized generic version of AstraZeneca's Seroquel XR in the US"></Deal><Deal id="246834" title="Luye Pharma to purchase AstraZeneca's Seroquel and Seroquel XR in the UK, China and other international markets          "></Deal><Deal id="253111" title="Laboratorios Bago to distribute and commercialize AstraZeneca’s Seroquel and Seroquel XR in Argentina"></Deal></Deals><PatentFamilies><PatentFamily id="1105960" number="WO-2007058593" title="Quetiapine in a controlled release formulation"></PatentFamily><PatentFamily id="2503373" number="WO-09745124" title="Pharmaceutical compositions."></PatentFamily><PatentFamily id="387345" number="EP-00240228" title="Thiazepine compounds"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hutchison Medipharma Enterprises Ltd" id="1011918"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="IntelliPharmaCeutics International Inc" id="1016256"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Intas Pharmaceuticals Ltd" id="1028220"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Osmotica Pharmaceutical Corp" id="1030119"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Handa Pharmaceuticals" id="1048449"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hanmi Holdings Co Ltd" id="1060189"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Endo International plc" id="1089706"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Akzo Nobel NV" id="13802"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AstraZeneca plc" id="14190"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bausch Health Companies Inc" id="17058"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mylan NV" id="18439"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Orion Corp" id="18693"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Torrent Pharmaceuticals Ltd" id="29175"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>